Biggest stock movers today: Walgreens Boots Alliance, Nike, Editas Medicine and more
ismagilov
Stock futures were higher on Friday as they look to close out a tough September on a more positive note.
Here are some of Friday's biggest stock movers:
Biggest stock gainers

Shares of Walgreens Boots Alliance (NASDAQ:WBA) advanced 7% on a report that the company is considering hiring former Cigna (CI) leader Tim Wentworth as its next CEO.

Footwear giant Nike (NYSE:NKE) surged over 7% after the company surpassed profit expectations in Q1 and saw a 10% drop in its stockpile of inventory, which indicated progress. CFO Matthew Friend said, âOur first-quarter results demonstrated the impact of staying on the offense over the past fiscal year. With a healthy marketplace and another quarter of brand and business momentum, we are strengthening our foundation for sustainable, profitable, long-term growth."
Shares of Editas Medicine (NASDAQ:EDIT) rose roughly 15% as Stifel analyst Dae Gon Ha raised the recommendation for the company to buy from hold and raised the price target to $17 from $9. âWe think EDIT-301âs (sickle cell disease [SCD]) progress has received minimal credit from investors. But with the YE23 goal to dose n = 20, in addition to the important regulatory insights expected from Exacel (CRSP, covered by Stifel colleague Ben Burnett), we think EDIT-301 deserves a fresh look,â the analyst wrote in a note to clients.
OPKO Health (NASDAQ:OPK) shares jumped more than 5% after ModeX Therapeutics won a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to develop antibodies to battle viral infectious disease threats. BARDA has awarded $59M for a Phase 1 clinical trial for a next-generation MSTAR multispecific antibody against SARS-CoV-2. The initiative builds on a collaboration between ModeX and the Vaccine Research Center. Additional funding of up to $109M may be available for other viral pathogens.

Biggest stock losers
Corcept Therapeutics (NASDAQ:CORT) experienced a 20% drop in its shares amid a patent trial with Teva Pharmaceutical (TEVA). The trial is over a patent for Cushing's syndrome drug Korlym, which Corcept marketed. In December 2021, Teva lost an attempt to invalidate a patent for Korlym. The trial, which began on Wednesday, is expected to result in Corcept losing the case.

Related stories:

NIKE, Inc. (NKE) Q1 2024 Earnings Call Transcript
Nike in charts: Q1 footwear revenue climbs from last year, but dips from Q4
Nike Earnings Preview: Low Expectations With Poor Sentiment; Comps Get Easier In FY '24
Editas Medicine, Inc. (EDIT) Cantor Global Healthcare Conference 2023 - (Transcript)
Nike GAAP EPS of $0.94 beats by $0.18, revenue of $12.94B misses by $60M